Response Oncology Valuation
Based on Macroaxis valuation methodology, the company cannot be evaluated at this time. Response Oncology recent Real Value cannot be determined due to lack of data. The prevailing price of Response Oncology is $0.0. Our model determines the value of Response Oncology from analyzing the company fundamentals such as Return On Equity of -7.24, operating margin of (0.01) %, and Shares Outstanding of 12.18 M as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Response Oncology's price fluctuation is out of control at this time. Calculation of the real value of Response Oncology is based on 3 months time horizon. Increasing Response Oncology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Response Oncology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Response Stock. However, Response Oncology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0 | Real 0.0 | Hype 0.0 |
The intrinsic value of Response Oncology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Response Oncology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Response Oncology helps investors to forecast how Response stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Response Oncology more accurately as focusing exclusively on Response Oncology's fundamentals will not take into account other important factors: Response Oncology Total Value Analysis
Response Oncology is at this time forecasted to have valuation of 16.62 M with market capitalization of 12, debt of 26.45 M, and cash on hands of 9.01 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Response Oncology fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
16.62 M | 12 | 26.45 M | 9.01 M |
Response Oncology Investor Information
The company recorded a loss per share of 4.16. Response Oncology had not issued any dividends in recent years. The entity had 0.2:1 split on the 3rd of November 1995. Based on the key measurements obtained from Response Oncology's financial statements, Response Oncology is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Response Oncology Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Response Oncology has an asset utilization ratio of 408.57 percent. This suggests that the Company is making $4.09 for each dollar of assets. An increasing asset utilization means that Response Oncology is more efficient with each dollar of assets it utilizes for everyday operations.Response Oncology Profitability Analysis
The company reported the previous year's revenue of 118.08 M. Net Loss for the year was (51.39 M) with profit before overhead, payroll, taxes, and interest of 28.17 M.About Response Oncology Valuation
Our relative valuation model uses a comparative analysis of Response Oncology. We calculate exposure to Response Oncology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Response Oncology's related companies.Response Oncology, Inc. does not have significant operations. Prior to the sale of its assets, it provided advanced cancer treatment services through outpatient facilities known as IMPACT Centers under the direction of practicing oncologists owned the assets of and managed the nonmedical aspects of oncology practices compounded and dispensed pharmaceuticals to certain oncologists for a fixed or cost plus fee and conducted outcomes research on behalf of pharmaceutical manufacturers. Response Oncology is traded on OTC Exchange in the United States.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Response Stock
If you are still planning to invest in Response Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Response Oncology's history and understand the potential risks before investing.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |